Background: Early diagnosis remains difficult because the early symptoms of thymoma are atypical.
Objectives: This study aimed to analyze the changes of serum proteins in the early stage of thymoma (stage I/II) by proteomics method and to screen and validate candidate biomarkers.
Methods: Proteins were extracted from 8 sera patients with stage I/II thymoma and 9 healthy controls. The levels of serum proteins were detected by data-independent acquisition (DIA) quantitative proteomics techniques, and the differential proteins were identified. The proteomic results were verified by enzyme-linked immunosorbent assay. Additionally, differentially expressed proteins were analyzed using receiver operating characteristic curves (ROC).
Results: There were 80 differentially expressed proteins between the patients with thymoma and the healthy control group, among which 39 were up-regulated and 41 were down-regulated. Differential protein enrichment is involved in environmental information processing, signaling molecules and interactions, and in the body system and the immune system. The analysis of receptor working characteristic curves showed that the areas under the curve of CORO1A, SAA1 and LTA4H were all larger than 0.8, indicating that these proteins had good diagnostic value.
Conclusion: CORO1A, SAA1 and LTA4H may be new biomarkers for early screening of thymoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/0109298665275655231103105924 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intra-Mesopore Immunoassay Based on Core-Shell Structured Magnetic Hierarchically Porous ZIFs.
ACS Sens
January 2025
Key Laboratory for Ultrafine Materials of Ministry of Education, School of Materials Science and Engineering, East China University of Science and Technology, Shanghai 200237, China.
It is crucial yet challenging to sensitively quantify low-abundance biomarkers in blood for early screening and diagnosis of various diseases. Herein, an analytical model of intra-mesopore immunoassay (IMIA) was proposed, which was competent to examine various biomarkers at the femtomolar level. The success is rooted in the design of an innovative superparamagnetic core-shell structure with FeO nanoparticles (NPs) at the core and hierarchically porous zeolitic imidazolate frameworks as a shell (FeO@HPZIF-8), achieved through a soft-template directed self-assembly coupled with confinement growth mechanism.
View Article and Find Full Text PDFDynamine 3 as a Diagnostic and Prognostic Biomarker in Pancreatic Cancer: Implications for Early Detection and Targeted Therapy.
Biomarkers
January 2025
Hacettepe University, Faculty of Medicine, Deparment of Medical Oncology, Ankara, Turkey.
Background: Dynamins are defined as a group of molecules with GTPase activity that play a role in the formation of endocytic vesicles and Golgi apparatus. Among them, DNM3 has gained recognition in oncology for its tumor suppressor role. Based on this, the aim of this study is to investigate the effects of the DNM3 gene in patients diagnosed with pancreatic cancer using bioinformatics databases.
View Article and Find Full Text PDFHighly Sensitive Digital and Analog Immunoassay Based on Submicron Magnetic Beads and Fluorescent Microspheres.
Anal Chem
January 2025
College of Chemistry and Molecular Sciences, Wuhan University, Wuhan 430072, China.
The detection of disease-related protein biomarkers plays a crucial role in the early diagnosis, treatment, and monitoring of diseases. The concentrations of protein biomarkers can vary significantly in different diseases or stages of the same disease. However, most of the existing analytical methods cannot simultaneously meet the requirements of high sensitivity and a wide dynamic range.
View Article and Find Full Text PDFEarly Use of Liraglutide for the Treatment of Acute COVID-19 Infection: An Open-Label Single-Center Phase II Safety Study with Biomarker Profiling.
Infect Dis Rep
January 2025
Royal Brompton Hospital, Part of GSTT NHS Foundation Trust, London SW3 6NP, UK.
Background: Glucagon-like peptide-1 (GLP-1) agonists are an existing treatment option for patients with insulin-resistant states, which elicit further pleiotropic effects related to immune cell recruitment and vascular inflammation. GLP-1 agonists downregulate the cluster of differentiation 147 (CD147) receptor, one of several receptors for the SARS-CoV-2 spike protein that mediate viral infection of host cells.
Methods: We conducted an open-label prospective safety and tolerability study including biomarker responses of the GLP-1 agonist Liraglutide, administered for 5 days as an add-on therapy to the standard of care within 48 h of presentation in a cohort of 13 patients hospitalized with COVID-19 pneumonia.
[Nephrology : what's new in 2024 (II)].
Rev Med Suisse
January 2025
Service de néphrologie, Département de médecine, Hôpitaux universitaires de Genève, Genève 14.
Certain molecules, such as GLP-1 agonists and endothelin antagonists, possess nephroprotective properties. When treating IgA nephropathy, endothelin antagonists and sibeprenlimab have shown effectiveness in slowing the progression of chronic kidney isease. Additionally, the infusion of amino acids can reduce the incidence of mild acute kidney injury following cardiac surgery.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!